Daratumumab Hyaluronidase-fihj
Showing 1 - 25 of 318
Multiple Myeloma Trial in United States (TTI-622, Daratumumab Hyaluronidase-fihj)
Recruiting
- Multiple Myeloma
- TTI-622
- Daratumumab Hyaluronidase-fihj
-
Basking Ridge, New Jersey
- +6 more
Dec 8, 2022
Plasma Cell Myeloma Trial in Philadelphia (Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life
Not yet recruiting
- Plasma Cell Myeloma
- Daratumumab and Hyaluronidase-fihj
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Aug 19, 2022
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance Trial in Washington (Daratumumab and
Not yet recruiting
- Peripheral Neuropathy
- Monoclonal Gammopathy of Undetermined Significance
- Daratumumab and hyaluronidase-fihj
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Sep 14, 2023
Multiple Myeloma Trial (Iberdomide, Daratumumab/rHuPH20 Co-formulation)
Not yet recruiting
- Multiple Myeloma
- Iberdomide
- Daratumumab/rHuPH20 Co-formulation
- (no location specified)
Oct 25, 2023
NSCLC With STK11/LKB1 Mutation Trial in New York (Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication,
Not yet recruiting
- Non-small Cell Lung Cancer With STK11/LKB1 Mutation
- Daratumumab and Hyaluronidase-fihj
- +2 more
-
New York, New YorkNYU Langone Health
Mar 29, 2023
Relapsed/Refractory Multiple Myeloma Trial in La Jolla (Ixazomib, Pomalidomide, Dexamethasone)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Ixazomib
- +3 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Mar 7, 2022
Antibody-mediated Rejection, Cardiac Transplant Trial in Rochester (Daratumumab and hyaluronidase-fihj)
Enrolling by invitation
- Antibody-mediated Rejection
- Cardiac Transplant
- Daratumumab and hyaluronidase-fihj
-
Rochester, MinnesotaMayo Clinic Rochester
Apr 11, 2022
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)
Recruiting
- Relapsed/Refractory
- Tafasitamab
- +8 more
-
Santa Fe, CaliforniaCalifornia Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022
T-cell Acute Lymphoblastic Leukemia Trial in Chicago (Daratumumab / Hyaluronidase Injection)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Daratumumab / Hyaluronidase Injection
-
Chicago, IllinoisNorthwestern
Jun 17, 2022
Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial in United States (TAK-981, Mezagitamab, Daratumumab and
Recruiting
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- TAK-981
- +2 more
-
Scottsdale, Arizona
- +11 more
Jan 6, 2022
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC
Active, not recruiting
- Multiple Myeloma
- Daratumumab Subcutaneous (SC) Administration
- Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
-
Atlanta, Georgia
- +11 more
Aug 11, 2022
Recurrent Plasma Cell Myeloma Trial in Houston (Daratumumab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2021
Hemolytic Anemia Trial in Lebanon (Daratumumab / Hyaluronidase Injection)
Recruiting
- Hemolytic Anemia
- Daratumumab / Hyaluronidase Injection
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Jun 15, 2022
Multiple Myeloma Trial in Rochester (procedure, biological, drug)
Not yet recruiting
- Multiple Myeloma
- Biospecimen Collection
- +12 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Sep 15, 2023
Multiple Myeloma Trial (Dara-SC, Blood for research assessments, Bone marrow for research assessments)
Withdrawn
- Multiple Myeloma
- Dara-SC
- +2 more
- (no location specified)
Jan 6, 2022
Multiple Myeloma Trial in Worldwide (Dara SC, Dara IV)
Active, not recruiting
- Multiple Myeloma
- Dara SC
- Dara IV
-
Boston, Massachusetts
- +145 more
Jan 17, 2023
Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)
Not yet recruiting
- Lymphoma, Primary Effusion
- Daratumumab SC
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 23, 2023
Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib 20 mg/m^2
- +4 more
-
Gilbert, Arizona
- +107 more
Dec 20, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Pomalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Woolloongabba, Queensland, Australia
- +117 more
Aug 3, 2022